UK ADHD Medication Review & Evidence Planner

Medication Response & Vitals

Record your 12-month timeline, somatic symptoms, and transition goals.

Current Prescribed Treatment

Desired Transition Target

Review Interval (Months)

Efficacy (1-5)

2/5

Weight Loss (kg)

Body Weight Loss (%)

Appetite Status

12-Month Weight & Tolerance Trajectory Clinically Significant (>10% Loss)

NICE Clinical Review Checklist (NG87)

Medical History & Baseline Checked Blood pressure, resting pulse, and baseline records validated.

Documented Unintended Weight Loss >10% Meets NICE caution criteria for adverse gastrointestinal impact.

Substance History: Past Self-Medication vs. Current Stability Pre-titration cannabis cessation addressed; constructive risk appraisal.

ADHD Executive Dysfunction Rebound Noted Diminishing focus/organization despite consistent daily dosing.

Core Consultation Talking Points (one per line)

Structured Review Agenda & Brief

Real-time consultation plan aligned with UK RTC and NICE NG87 guidelines.

Reported Efficacy 2 / 5 (Suboptimal)

Weight Loss (12 Mo) -8.0 kg (-10.5%)

Prioritized Clinical Agenda

NICE NG87 Guideline Transition Justification

First-line Treatment Review: Atomoxetine is valid for non-responders or intolerance, but NICE recommends reassessing if therapeutic response wanes after initial 6–12 months.
Adverse Weight/Appetite Impact: A documented 10.5% weight loss satisfies clinical threshold for treatment modification or specialist nutrition/pharmacotherapy review.
Constructive Substance Dialogue: Historical recreational cannabis ceased pre-titration; NICE guidelines emphasize collaborative risk management rather than blanket denial of first-line stimulant care.

Requested Clinician Outcome

Agreement to titrate onto Stimulant medication (e.g., Methylphenidate / Lisdexamfetamine) under RTC specialist supervision, including baseline cardiovascular metrics and appetite monitoring.

Clinical References & Guidance:

NICE Guideline NG87: Attention deficit hyperactivity disorder: diagnosis and management (Updated UK Guidance). NHS Right to Choose (RTC) provider review framework (Harrow Health / Clinical Partners / Psychiatry UK protocols). This tool generates a personal preparation outline for annual ADHD consultations; always discuss clinical adjustments directly with your NHS or RTC psychiatrist.